Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus (Q38778064)

6 September 2017

Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

6 September 2017

1 reference

1 reference

non-alcoholic fatty liver

1 reference

1 reference

Yoshio Sumida

1

1 reference

6 September 2017

Yuya Seko

series ordinal

2

1 reference

6 September 2017

Masashi Yoneda

series ordinal

3

1 reference

6 September 2017

Japan Study Group of NAFLD (JSG-NAFLD)

series ordinal

4

1 reference

6 September 2017

language of work or name

1 reference

26 December 2016

1 reference

6 September 2017

1 reference

6 September 2017

47

1 reference

6 September 2017

266-280

1 reference

6 September 2017

4

1 reference

Causes of death in Japanese diabetics: A questionnaire survey of 18,385 diabetics over a 10-year period

6 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Diabetes mellitus and metformin in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Advances in the treatment of type 2 diabetes: impact of dulaglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effect of vildagliptin on hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-li

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Predictors of response to ipragliflozin treatment in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β-cell function and reduction of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Functional expression of sodium-glucose transporters in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12856

21 January 2018

Identifiers

DOI

10.1111/HEPR.12856

1 reference

6 September 2017

1 reference